AtCor's pressure rises
Wednesday, 30 July, 2008
AtCor Medical Holdings [ASX: ACG] has recorded its best sales figures ever, totalling around $6.5 million in 2008.
This represents a 47 per cent increase over last year's sales.
The largest gain was in Europe, where sales increased by 59 per cent. In North America sales increased by 46 per cent, and rest of the world by eight per cent.
The company's main product, the SphygmoCor system, identifies the effects of reflected blood pressure in the central aortic pressure wave.
Last week, the company reported two contracts for a total of US$1.6 million for pharmaceutical company.
Scientists find new driver of ovarian cancer spread
A cell surface receptor known as F2R could serve as both a diagnostic marker for ovarian cancer...
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
